Division

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Retrieved on: 
Wednesday, January 11, 2023
AGN, Physician, BLU, Albert Einstein College of Medicine, Education, Internal medicine, Biochemistry, Montefiore Medical Center, Division, American College, CSE, P2X3, Mount Sinai Medical Center, Critical Care Medicine (journal), Critical care, Conference, Patient, American College of Chest Physicians, Chronic cough, European Respiratory Society, Cough, Acquisition, USD, Merck & Co., Ifenprodil, Pharmaceutical industry, New York University, Medicine, Gefapixant, NYU

Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).

Key Points: 
  • Dr. Dicpinigaitis will be advising the Company on its planned 180 patient, Phase 2b chronic cough study of NP-120 (Ifenprodil).
  • Dr. Dicpinigaitis is board-certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine.
  • “We are very pleased that Dr. Dicpinigaitis has joined Algernon as a medical advisor,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • At the time, Gefapixant had interim data from a Phase 2b dose-escalation study in refractory chronic cough.

Adaptive Research Expands Clinical Programs and Appoints Perminder Bhatia, M.D. as Head of Neurology

Retrieved on: 
Tuesday, January 10, 2023
Perminder Sachdev, Albert Einstein College of Medicine, University at Buffalo, Division, Head, State university system, Health, Community Health Systems, Patient, MBBS, SAN, Clinical trial, Gastroenterology, Nuclear medicine, Physician, Buffalo, Pharmaceutical industry, Medical imaging, Neurology

SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose to democratize clinical trials by integrating community physicians into the clinical trial process, today announced that Perminder Bhatia, M.D.

Key Points: 
  • SAN FRANCISCO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization with a unique purpose to democratize clinical trials by integrating community physicians into the clinical trial process, today announced that Perminder Bhatia, M.D.
  • “2022 was a year of tremendous growth for Adaptive Research and with our continued expansion we are thrilled to have Perminder join our team,” said Brajesh Agrawal, M.D., Chief Medical Officer.
  • “His extensive experience in neurology combined with his proficiency in conducting clinical trials makes him the ideal candidate to lead our neurology division.
  • Since 2003, Dr. Bhatia has completed more than 100 clinical trials and has published numerous research papers.

3DR Labs welcomes board-certified diagnostic radiologist to Cardiac Center of Excellence

Retrieved on: 
Tuesday, January 10, 2023
Associate, University, National Institutes of Health Clinical Center, Software testing certification board, Case Western Reserve University, Division, University of Pittsburgh Medical Center, American Board of Commissioners for Foreign Missions, Society, The Massachusetts, MD, Magnetic resonance, Massachusetts General Hospital, Hospital, CT, Society of Cardiovascular Computed Tomography, American Board of Radiology, Chief Medical Advisor to the President, MGH, Radiology, HMS, Pennsylvania Hospital, Weatherhead School of Management, MRI, Harvard Medical School, OH, MBA, Labs, Medical imaging, Health

Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.

Key Points: 
  • Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.
  • Dr. Ghoshhajra is a board-certified Diagnostic Radiologist with advanced training in Cardiovascular Computed Tomography (CT) and Cardiovascular Magnetic Resonance Imaging (MRI).
  • As the Medical Advisor to 3DR’s Cardiac Center of Excellence, Dr. Ghoshhajra’s vast experience in advanced cardiovascular imaging (including CT and MRI) will support 3DR’s ability to deliver the highest quality post processing services in the rapidly expanding advanced cardiac imaging market.
  • “We are incredibly excited to have Dr. Ghoshhajra’s leadership, expertise and capability in our new Cardiac Center of Excellence”, said Dave Levine, Vice President and General Manager, 3DR Labs.

Activ Surgical Announces Completion of First AI-Enabled Case Using Its ActivSight™ Intelligent Light

Retrieved on: 
Monday, January 9, 2023
Software, Hardware, Surgery, Health, Artificial Intelligence, Hospitals, Health Technology, Technology, Union, OR, Division, CE marking, Trial of the century, Safety, Surgeon, MD, FDA, Ohio State University Wexner Medical Center, AI, Artificial intelligence, Mode, Ohio State University, Intelligence, Rectum, Cancer, Intelligent lighting, Surgery, Perfusion, Health, Medical device, Medical imaging

Activ Surgical , a digital surgery pioneer, today announced that it has completed its first artificial intelligence (AI)-enabled case using its product, ActivSight™ Intelligent Light (ActiveSight), which aims to provide enhanced visualization and real-time, on-demand surgical insights in the operating room.

Key Points: 
  • Activ Surgical , a digital surgery pioneer, today announced that it has completed its first artificial intelligence (AI)-enabled case using its product, ActivSight™ Intelligent Light (ActiveSight), which aims to provide enhanced visualization and real-time, on-demand surgical insights in the operating room.
  • ActivSight is an easy-to-adapt module that seamlessly attaches to today’s laparoscopic and robotic systems and integrates with standard monitors.
  • Activ Surgical is currently conducting a clinical study with Ohio State Wexner Medical Center to evaluate the utility and usability of ActivSight.
  • “At Activ Surgical, we are driven to learn from every procedure using enhanced, real-time visualization capabilities combined with augmented reality, artificial intelligence and machine learning technology so that we can deliver intelligent information to doctors around the world to reduce surgical complication rates,” said Manisha Shah-Bugaj, Chief Executive Officer at Activ Surgical.

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Retrieved on: 
Monday, January 9, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Disease, The New England Journal of Medicine, University, Nutrition, Division, Trial of the century, Safety, University of Florida, Arrowhead, Head, F2, Arrowhead Pharmaceuticals, SEQUOIA, Patient, Week, Webcast, RNA interference, F3, Fibrosis, Serum, Particle-size distribution, Liver, Liver disease, Inflammation, Outline, Multimedia, TAK, AATD, Physician, Pharmaceutical industry, Dietary supplement, Medical imaging, Takeda, Gastroenterology

Takeda ( TSE:4502/NYSE:TAK ) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD).
  • The companies also provided an outline of a Phase 3 study that was co-developed by Takeda and Arrowhead and will be conducted by Takeda.
  • Additional SEQUOIA study results are planned to be presented at a future medical meeting and submitted for publication.
  • View the full release here: https://www.businesswire.com/news/home/20230109005210/en/
    “Currently there is no treatment for liver disease from alpha-1 antitrypsin deficiency.

Bastyr University Doctor of Naturopathic Medicine Candidate Sarah JaeHwa Park Earns Harvard Medical School Postdoctoral Fellowship

Retrieved on: 
Wednesday, January 11, 2023
Harvard T.H. Chan School of Public Health, Harvard Medical School, Research, Naturopathy, Division, SAN, Alternative medicine, Disease, Bastyr University, Harvard University, Public health, Medical school, Hospital, Brigham and Women's Hospital, Alternative, Parkinson's disease, Pharmaceutical industry

SAN DIEGO, Jan. 11, 2023 /PRNewswire-PRWeb/ -- Bastyr University is proud to announce Class of 2023 Candidate for the Doctor of Naturopathic Medicine Sarah JaeHwa Park accepted a position at Harvard Medical School as a postdoctoral fellow in integrative medicine beginning July 2023. Ms. Park is the first naturopathic doctor to join this fellowship, and one of the first naturopathic doctors in the Harvard network.

Key Points: 
  • Harvard Medical School accepts Bastyr University Class of 2023 Doctor of Naturopathic Medicine Candidate Sarah JaeHwa Park as a postdoctoral fellow in integrative medicine.
  • SAN DIEGO, Jan. 11, 2023 /PRNewswire-PRWeb/ -- Bastyr University is proud to announce Class of 2023 Candidate for the Doctor of Naturopathic Medicine Sarah JaeHwa Park accepted a position at Harvard Medical School as a postdoctoral fellow in integrative medicine beginning July 2023.
  • Ms. Park is the first naturopathic doctor to join this fellowship, and one of the first naturopathic doctors in the Harvard network.
  • "Ms. Park earned her postdoctoral fellowship at Harvard Medical School, and it is a substantive acknowledgement of the valuable role naturopathic physicians play in disease and medical research today," says Bastyr University President Devin Byrd, Ph.D. "Throughout her time at Bastyr University, Ms. Park collaborated with faculty to publish research furthering the treatment of Parkinson's disease.

Contractors Optimistic about 2023 Construction Outlook

Retrieved on: 
Wednesday, January 11, 2023
Journal of Business Forecasting, Schwager, Optimism, Workforce, Division, AGC, Public sector, Multi, Steel, Former, Sage, Construction

CHARLOTTE, N.C., Jan. 11, 2023 /PRNewswire/ -- Carolinas AGC (CAGC) announces that the construction outlook for 2023 looks to be good! On January 4, AGC of America and Sage released its 2023 National and State Hiring and Business Forecast for Commercial Construction during its annual Construction Hiring & Business Outlook at a virtual media briefing and simultaneous Facebook (facebook.com/AGCA) livestream. Panelists included Steve Sandherr, CEO of AGC of America, Ken Simonson, Chief Economist of AGC of America, Casey Schwager, Former CAGC Board Chair and Division Vice President of King Asphalt, and several others.

Key Points: 
  • CHARLOTTE, N.C., Jan. 11, 2023 /PRNewswire/ -- Carolinas AGC (CAGC) announces that the construction outlook for 2023 looks to be good!
  • On January 4, AGC of America and Sage released its 2023 National and State Hiring and Business Forecast for Commercial Construction during its annual Construction Hiring & Business Outlook at a virtual media briefing and simultaneous Facebook (facebook.com/AGCA) livestream.
  • While contractors are optimistic about the construction outlook for 2023, they expect different market conditions for the coming year than what they experienced in 2022.
  • Contractors are less optimistic about many private-sector segments than they were a year ago, while their expectations for the public sector market have remained relatively bullish.

Geneoscopy's Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

Retrieved on: 
Tuesday, January 10, 2023
Cancer, AA, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biomarker, Division, Risk, Colorectal cancer, Trial of the century, Sale, Patient, CRC, Degenerative disease, American Gastroenterological Association, FDA, Hepatology, Endoscopy, Diagnosis, Collection, RNA, Medical imaging, Pharmaceutical industry, Medical device, Gastroenterology

ST. LOUIS, Jan. 10, 2023 /PRNewswire/ -- Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced favorable results from the CRC-PREVENT trial – a pivotal clinical trial evaluating the efficacy of its noninvasive, stool-based, at-home diagnostic screening test to detect colorectal cancer (CRC) and advanced adenomas (AA) in average-risk individuals. In the trial, Geneoscopy's stool-based screening test met the clinical endpoints across all primary outcome measures, including sensitivity and specificity for CRC and AA.

Key Points: 
  • In the trial, Geneoscopy's stool-based screening test met the clinical endpoints across all primary outcome measures, including sensitivity and specificity for CRC and AA.
  • "...Our test may allow patients to get appropriate treatment, in some cases, even before cancer develops."
  • Efficacy results from the study include:
    These sensitivity results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.
  • The large-scale prospective clinical study data demonstrate that this noninvasive CRC screening test can accurately detect if people have cancer and if they have advanced adenomas that put them at higher risk of developing cancer.

MedTherapy, a Boston-based Biotech, plans to Reduce the Cost and Time to Manufacture CAR-T Cancer Gene therapies to One-fourth

Retrieved on: 
Monday, January 9, 2023
Dana–Farber Cancer Institute, DVM, Cancer, Harvard Medical School, Partnership, GMP, Biotechnology, Division, Disease, Patient, JPMorgan Chase, Conference, Transfection, Pharmaceutical industry, Vaccine, MD, Leukemia, Medicine

"MedTherapy was founded with a mission to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible.

Key Points: 
  • "MedTherapy was founded with a mission to make the exorbitantly expensive CAR-T cell cancer gene therapy more affordable and accessible.
  • CAR-T therapy is plagued by several constraints responsible for its exorbitant cost and complex manufacturing processes, viz.
  • Together, our integrated and innovative approaches lead to dramatic reduction in the cost and time to manufacture, and thus the reduced cost of the CAR-T cell gene therapy.
  • Our technology is being developed to manufacture CAR-T cells cancer gene therapy in a few days instead of the industry average of four to six weeks.

Kelley Drye Accelerates into New Year With the Addition of Former Prosecutor Sandra Musumeci and Veteran FTC Privacy Attorney Katherine White

Retrieved on: 
Monday, January 9, 2023
Government, Denver District Attorney's Office, White collar, National Association, Assistant District Secretary of Chama Cha Mapinduzi, Manhattan Project, New York City Department of Investigation, City, National Association of Attorneys General, Division, Risk, Kelley Drye & Warren, Kate, FTC, Private practice, Prosecutor General's Office of Azerbaijan, Homicide, Consumer protection, Bureau, Kate White, Intelligence Identities Protection Act, Private investigator, Privacy

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Kelley Drye & Warren LLP began the New Year by adding depth in two practice areas of critical importance to clients.

Key Points: 
  • NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Kelley Drye & Warren LLP began the New Year by adding depth in two practice areas of critical importance to clients.
  • Kelley Drye begins the New Year by adding depth in two practice areas of critical importance to clients.
  • Kate advises clients on all aspects of consumer protection law, with a particular focus on privacy, information security, and financial services regulations.
  • "The addition of Kate White and Sandy Musumeci, in addition to other recent laterals from government posts, enables us to deliver insights spanning legal, legislative, regulatory, and enforcement angles."